title: Solitary metastasis in a nasal fossa as the first manifestation of a renal carcinoma.
abstract: Renal cell carcinoma is an uncommon tumor in adults. Metastasis in the nasal fossa is rare, and can become apparent as a result of repeated epistaxis. We report a patient with renal cell carcinoma presenting with epistaxis secondary to a metastasis in the right nasal fossa. The primary tumor was treated with nephrectomy and the nasal fossa metastasis was treated successfully with embolization, chemoimmunotherapy, surgery, and radiotherapy. The presence of repeated epistaxis may very occasionally be the first symptom of renal cell carcinoma, and systemic treatment combined with local treatment may enable adequate control of the disease.
authors.affiliation: Medical Oncology Section, Carlos Haya Regional University Hospital, Málaga, Spain. manuelcobodols@yahoo.es
authors.forename: Manuel
authors.initials: M
authors.lastname: Cobo-Dols
authors.forename: Inmaculada
authors.initials: I
authors.lastname: Alés-Díaz
authors.forename: Ester
authors.initials: E
authors.lastname: Villar-Chamorro
authors.forename: Silvia
authors.initials: S
authors.lastname: Gil-Calle
authors.forename: Julia
authors.initials: J
authors.lastname: Alcaide-García
authors.forename: Alvaro
authors.initials: A
authors.lastname: Montesa-Pino
authors.forename: Vanesa
authors.initials: V
authors.lastname: Gutiérrez-Calderón
authors.forename: Manuel
authors.initials: M
authors.lastname: Benavides-Orgaz
mesh_terms: D018262:Adenocarcinoma, Clear Cell / Q000473:pathology / Q000556:secondary* / Q000628:therapy; D000964:Antimetabolites, Antineoplastic / Q000627:therapeutic use; D000972:Antineoplastic Agents, Phytogenic / Q000627:therapeutic use; D002292:Carcinoma, Renal Cell / Q000473:pathology / Q000556:secondary* / Q000628:therapy; D003131:Combined Modality Therapy; D004621:Embolization, Therapeutic; D004844:Epistaxis / Q000209:etiology; D017809:Fatal Outcome; D005472:Fluorouracil / Q000627:therapeutic use; D006801:Humans; D007155:Immunologic Factors / Q000627:therapeutic use; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000627:therapeutic use; D007376:Interleukin-2 / Q000627:therapeutic use; D007680:Kidney Neoplasms / Q000175:diagnosis* / Q000473:pathology / Q000628:therapy; D008175:Lung Neoplasms / Q000556:secondary / Q000601:surgery; D008197:Lymph Node Excision; D008297:Male; D008875:Middle Aged; D009296:Nasal Cavity; D009392:Nephrectomy; D009669:Nose Neoplasms / Q000175:diagnosis / Q000556:secondary* / Q000628:therapy; D009919:Orchiectomy; D011013:Pneumonectomy / Q000379:methods; D018714:Radiotherapy, Adjuvant; D011994:Recombinant Proteins; D013736:Testicular Neoplasms / Q000556:secondary / Q000601:surgery; D014057:Tomography, X-Ray Computed; D014747:Vinblastine / Q000627:therapeutic use
chemical_list: D000964:Antimetabolites, Antineoplastic; D000972:Antineoplastic Agents, Phytogenic; D007155:Immunologic Factors; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D007376:Interleukin-2; D011994:Recombinant Proteins; D014747:Vinblastine; D005472:Fluorouracil